52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis

OBJECTIVE: To compare the 52-week efficacy and safety of SB4 [an etanercept biosimilar] with reference etanercept (ETN) in patients with active RA. METHODS: In a phase 3, randomized, double-blind, multicentre study, patients with moderate to severe RA despite MTX treatment were randomized to receive...

Descripción completa

Detalles Bibliográficos
Autores principales: Emery, Paul, Vencovský, Jiří, Sylwestrzak, Anna, Leszczyński, Piotr, Porawska, Wieslawa, Baranauskaite, Asta, Tseluyko, Vira, Zhdan, Vyacheslav M., Stasiuk, Barbara, Milasiene, Roma, Barrera Rodriguez, Aaron Alejandro, Cheong, Soo Yeon, Ghil, Jeehoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850652/
https://www.ncbi.nlm.nih.gov/pubmed/28968793
http://dx.doi.org/10.1093/rheumatology/kex269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850652/
https://www.ncbi.nlm.nih.gov/pubmed/28968793
http://dx.doi.org/10.1093/rheumatology/kex269

Ejemplares similares